| An inflammatory cytokine signature predicts COVID-19 severity and survival DM Del Valle, S Kim-Schulze, HH Huang, ND Beckmann, S Nirenberg, ... Nature medicine 26 (10), 1636-1643, 2020 | 2513 | 2020 |
| Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma RJ Motzer, M Mazumdar, J Bacik, W Berg, A Amsterdam, J Ferrara Journal of clinical oncology 17 (8), 2530-2530, 1999 | 2251 | 1999 |
| Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma RJ Motzer, J Bacik, BA Murphy, P Russo, M Mazumdar Journal of clinical oncology 20 (1), 289-296, 2002 | 2091 | 2002 |
| Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma RJ Motzer, J Bacik, LH Schwartz, V Reuter, P Russo, S Marion, ... Journal of clinical oncology 22 (3), 454-463, 2004 | 1000 | 2004 |
| DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia ME Figueroa, S Lugthart, Y Li, C Erpelinck-Verschueren, X Deng, ... Cancer cell 17 (1), 13-27, 2010 | 997 | 2010 |
| Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy DF Bajorin, PM Dodd, M Mazumdar, M Fazzari, JA McCaffrey, HI Scher, ... Journal of Clinical Oncology 17 (10), 3173-3181, 1999 | 815 | 1999 |
| Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion … SM Larson, Y Erdi, T Akhurst, M Mazumdar, HA Macapinlac, RD Finn, ... Clinical Positron Imaging 2 (3), 159-171, 1999 | 696 | 1999 |
| Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma AB Siegel, EI Cohen, A Ocean, D Lehrer, A Goldenberg, JJ Knox, H Chen, ... Journal of Clinical Oncology 26 (18), 2992-2998, 2008 | 613 | 2008 |
| Perioperative comparative effectiveness of anesthetic technique in orthopedic patients SG Memtsoudis, X Sun, YL Chiu, O Stundner, SS Liu, S Banerjee, ... Anesthesiology 118 (5), 1046-1058, 2013 | 584 | 2013 |
| Treatment outcome and survival associated with metastatic renal cell carcinoma of non–clear-cell histology RJ Motzer, J Bacik, T Mariani, P Russo, M Mazumdar, V Reuter Journal of Clinical Oncology 20 (9), 2376-2381, 2002 | 578 | 2002 |
| Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety J Poeran, R Rasul, S Suzuki, T Danninger, M Mazumdar, M Opperer, ... Bmj 349, 2014 | 566 | 2014 |
| Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer JG Guillem, DB Chessin, AM Cohen, J Shia, M Mazumdar, W Enker, ... Annals of surgery 241 (5), 829-838, 2005 | 497 | 2005 |
| Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA S Worgall, D Sondhi, NR Hackett, B Kosofsky, MV Kekatpure, N Neyzi, ... Human gene therapy 19 (5), 463-474, 2008 | 478 | 2008 |
| Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma MW Kattan, MS Karpeh, M Mazumdar, MF Brennan Journal of clinical oncology 21 (19), 3647-3650, 2003 | 470 | 2003 |
| Endoscopic pituitary surgery: a systematic review and meta-analysis A Tabaee, VK Anand, Y Barrón, DH Hiltzik, SM Brown, A Kacker, ... Journal of neurosurgery 111 (3), 545-554, 2009 | 459 | 2009 |
| Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. WK Kelly, HI Scher, M Mazumdar, V Vlamis, M Schwartz, SD Fossa Journal of clinical oncology 11 (4), 607-615, 1993 | 452 | 1993 |
| Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors RJ Motzer, A Amsterdam, V Prieto, J Sheinfeld, V Murty, M Mazumdar, ... The Journal of urology 159 (1), 133-138, 1998 | 447 | 1998 |
| Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. JA McCaffrey, S Hilton, M Mazumdar, S Sadan, WK Kelly, HI Scher, ... Journal of Clinical Oncology 15 (5), 1853-1857, 1997 | 440 | 1997 |
| Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision‐making about cancer treatments M Mazumdar, JR Glassman Statistics in medicine 19 (1), 113-132, 2000 | 420 | 2000 |
| Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for … RJ Motzer, CJ Nichols, KA Margolin, J Bacik, PG Richardson, ... Journal of Clinical Oncology 25 (3), 247-256, 2007 | 408 | 2007 |
Stavros MemtsoudisHospital for Special Surgery -Weill Cornell Medical CollegeEmail confirmado em hss.edu
